Denteric therapies


About Denteric

We are a clinical-stage biotech company developing therapies with the potential to treat diseases associated with Porphyromonas gingivalis (Pg), such as periodontal disease.

Our first product is a therapy designed to neutralise and clear virulence factors (toxins) produced by Pg. 

GPV381 - An immunotherapy targeting major virulence factors produced by P. gingivalis (Pg)

Our Therapies

Denteric is developing therapies designed to inhibit and clear up the microbial toxins that cause periodontal disease (periodontitis). 

Our therapies aim to reduce the inflammation and bleeding that contribute to tooth loss by preventing the tissue destruction caused by Pg.

Common symptoms associated with periodontal disease include bleeding or swollen gums, tooth sensitivity, loose teeth, and bad breath.  Always seek advice from a healthcare professional such as a dentist or periodontist.

Join a Clinical Trial

If you would like to take part in a healthy volunteer safety trial for our therapeutic vaccine in Melbourne, please register your interest with our Clinical Trial Partner Nucleus Network.

Learn more about our clinical trial.

Our Investors

Thanks to investment from Brandon Capital, CSL and The University of Melbourne, we are currently developing safe and convenient therapies that will make the treatment of severe periodontal disease much less painful, more reliable and effective.

Denteric People

Our team is filled with globally recognised experts in the field of Porphyromonas gingivalis research and immunotherapy development. Learn more about the people who are on a mission to develop the therapies that make severe periodontal disease a thing of the past.

Learn more